New TB Treatment Shows Promising Results, Could Revolutionize Cure Rates and Patient Care. Researchers have made a breakthrough in the fight against killer tuberculosis (TB), with a new antibiotic, sorfequiline, showing stronger action against the deadly bacteria than existing treatments.
The World Health Organization (WHO) notes that TB remains a major global public health problem, responsible for over 1.2 million deaths last year alone. With aid cuts and falling short of targets to end TB as a public health threat by this decade, the WHO is calling on researchers to make progress.
A recent trial involving 309 people across 22 sites in South Africa, the Philippines, Georgia, Tanzania, and Uganda found that sorfequiline-based regimens could be used for anyone testing positive. The treatment showed comparable safety profiles to existing treatments while offering stronger action against TB bacteria.
According to Dr Maria Beumont, vice-president of the TB Alliance, patients could now receive a treatment immediately without waiting to understand their specific situation. This is crucial as access to swift diagnostic tests for TB is patchy, and it can take days or weeks in some places for doctors to get laboratories to identify the type of TB a patient has.
The trial's results have generated excitement among researchers, with some reporting "incredible" improvements in treatment outcomes. The hope is that this new treatment could lead to shorter treatment times, fewer side effects, and less strain on healthcare systems.
However, Dr Kavindhran Velen, chief scientific officer at the International Union against Tuberculosis and Lung Disease, notes that applying this universal TB treatment universally may have downsides. He warns that overexposing patients to unnecessary treatment could lead to unintended consequences, such as discouraging investments in wider innovations like laboratories and testing.
Despite these concerns, researchers remain optimistic about the potential of sorfequiline to revolutionize TB treatment. The TB Alliance plans to launch a phase-3 clinical trial in 2026, with hopes that it will further improve cure rates and patient care.
The World Health Organization (WHO) notes that TB remains a major global public health problem, responsible for over 1.2 million deaths last year alone. With aid cuts and falling short of targets to end TB as a public health threat by this decade, the WHO is calling on researchers to make progress.
A recent trial involving 309 people across 22 sites in South Africa, the Philippines, Georgia, Tanzania, and Uganda found that sorfequiline-based regimens could be used for anyone testing positive. The treatment showed comparable safety profiles to existing treatments while offering stronger action against TB bacteria.
According to Dr Maria Beumont, vice-president of the TB Alliance, patients could now receive a treatment immediately without waiting to understand their specific situation. This is crucial as access to swift diagnostic tests for TB is patchy, and it can take days or weeks in some places for doctors to get laboratories to identify the type of TB a patient has.
The trial's results have generated excitement among researchers, with some reporting "incredible" improvements in treatment outcomes. The hope is that this new treatment could lead to shorter treatment times, fewer side effects, and less strain on healthcare systems.
However, Dr Kavindhran Velen, chief scientific officer at the International Union against Tuberculosis and Lung Disease, notes that applying this universal TB treatment universally may have downsides. He warns that overexposing patients to unnecessary treatment could lead to unintended consequences, such as discouraging investments in wider innovations like laboratories and testing.
Despite these concerns, researchers remain optimistic about the potential of sorfequiline to revolutionize TB treatment. The TB Alliance plans to launch a phase-3 clinical trial in 2026, with hopes that it will further improve cure rates and patient care.